Chronic Myelomonocytic Leukemia clinical trials at UCLA
1 in progress, 0 open to eligible people
Showing trials for
Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Sorry, in progress, not accepting new patients
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy
Los Angeles 5368361, California 5332921 and other locations
Last updated: